Literature DB >> 11328289

Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.

I Hann1, A Vora, G Harrison, C Harrison, O Eden, F Hill, B Gibson, S Richards.   

Abstract

The single most important prognostic determinant in childhood acute lymphoblastic leukaemia (ALL) is effective therapy and changes in therapy may influence the significance of other risk factors. The effect of intensified therapy on the importance of currently recognized phenotypic and genotypic determinants of outcome was assessed in 2090 children enrolled on the Medical Research Council United Kingdom acute lymphoblastic leukaemia XI (MRC UKALL XI) protocol. Treatment allocation was not determined by risk factors. Multivariate analysis confirmed the dominant influence on prognosis of age, sex and presenting white cell count (WCC). After allowing for these features, blast karyotype, d 8 marrow blast percentage and remission status at the end of induction therapy were the only remaining significant predictors of outcome. Organomegaly, haemoglobin concentration, French--American--British type, body mass index, presence of central nervous system disease at diagnosis, immunophenotype and presence of TEL/AML1 fusion gene (examined in a subset of 659 patients) either had no significant effect on outcome or were significant only in univariate analysis. Among karyotype abnormalities with an independent influence on prognosis, high hyperdiploidy (> 50 chromosomes) was shown to be favourable, whereas near haploidy (23--29 chromosomes), presence of the Philadelphia chromosome, t(4;11) and abnormalities affecting the short arm of chromosome 9 [abn (9p)] were adverse risk factors. Early responders to therapy, determined by residual marrow infiltration after 8 d of induction therapy, had a good outcome, while the small proportion of patients who did not achieve a complete remission by the end of induction therapy had a poor outcome. A third block of late intensification was shown to improve event-free survival by 8% at 5 years. The effect of these risk factors was not significantly different between those randomized to the third intensification block and those not randomized to a third block.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328289     DOI: 10.1046/j.1365-2141.2001.02668.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.

Authors:  Karen R Rabin; M Monica Gramatges; Michael J Borowitz; Shana L Palla; Xiaodong Shi; Judith F Margolin; Patrick A Zweidler-McKay
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

2.  Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.

Authors:  J M Chessells; G Harrison; S M Richards; C C Bailey; F G Hill; B E Gibson; I M Hann
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

3.  Balancing high accrual and ethical recruitment in paediatric oncology: a qualitative study of the 'look and feel' of clinical trial discussions.

Authors:  Lucie M T Byrne-Davis; Peter Salmon; Katja Gravenhorst; Tim O B Eden; Bridget Young
Journal:  BMC Med Res Methodol       Date:  2010-10-22       Impact factor: 4.615

4.  A unique complex translocation involving six different chromosomes in a case of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and adverse prognosis.

Authors:  Walid Al Achkar; Abdulsamad Wafa; Hasmik Mkrtchyan; Faten Moassass; Thomas Liehr
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

5.  Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.

Authors:  Mignon L Loh; Meredith A Goldwasser; Lewis B Silverman; Wing-Man Poon; Shashaank Vattikuti; Angelo Cardoso; Donna S Neuberg; Kevin M Shannon; Stephen E Sallan; D Gary Gilliland
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

6.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

7.  The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.

Authors:  Marissa A H den Hoed; Saskia M F Pluijm; Hester A de Groot-Kruseman; Mariël L te Winkel; Martha Fiocco; Erica L T van den Akker; Peter Hoogerbrugge; Henk van den Berg; Jan A Leeuw; Marrie C A Bruin; Dorine Bresters; Anjo J P Veerman; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2014-10-10       Impact factor: 9.941

8.  Analysis of ZAP70 expression in adult acute lymphoblastic leukaemia by real time quantitative PCR.

Authors:  Geothy Chakupurakal; Andrew Bell; Mike Griffiths; Farooq Wandroo; Paul Moss
Journal:  Mol Cytogenet       Date:  2012-05-01       Impact factor: 2.009

9.  Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.

Authors:  S Krishnan; R Wade; A V Moorman; C Mitchell; S E Kinsey; T O B Eden; C Parker; A Vora; S Richards; V Saha
Journal:  Leukemia       Date:  2009-12-17       Impact factor: 11.528

10.  Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.

Authors:  W L Salzer; M Devidas; W L Carroll; N Winick; J Pullen; S P Hunger; B A Camitta
Journal:  Leukemia       Date:  2009-12-17       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.